Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Innoviva, Inc. - Common Stock
(NQ:
INVA
)
22.66
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innoviva, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 18, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 02, 2023
From
Innoviva, Inc.
Via
Business Wire
Overview Of Value Stocks In The Healthcare Sector
↗
July 31, 2023
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
↗
May 15, 2023
Via
Benzinga
5 Value Stocks In The Healthcare Sector
↗
May 08, 2023
Via
Benzinga
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
↗
April 18, 2023
Via
Benzinga
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
↗
July 11, 2023
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.
Via
InvestorPlace
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
↗
May 24, 2023
Via
Benzinga
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
What 4 Analyst Ratings Have To Say About Innoviva
↗
March 03, 2023
Via
Benzinga
Innoviva Earnings Perspective: Return On Capital Employed
↗
December 19, 2022
Via
Benzinga
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
↗
May 16, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces Retirement of Board Chairman
April 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Elon Musk Says US Intel Agencies Had Access To Twitter DMs, Alibaba's Ant IPO Might Actually See Light, Airbus Pushes Some 2024 Deliveries: Today's Top Stories
↗
April 18, 2023
Benzinga Elon Musk Drops Bombshell: US Intel Agencies Were Reading Your Twitter DMs
Via
Benzinga
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory Committee
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Stock Trading Halted Today
April 17, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
March 13, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
February 28, 2023
From
Innoviva, Inc.
Via
Business Wire
Four Undervalued Healthcare Stocks for 2023
January 06, 2023
These four health care stocks could be undervalued: Pfizer Inc., Regeneron Pharmaceuticals Inc., Innoviva Inc. and Exelixis Inc.
Via
MarketBeat
Innoviva Announces FDA Acceptance and Priority Review of New Drug Application for Sulbactam-Durlobactam (SUL-DUR)
November 30, 2022
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 09, 2022
From
Innoviva, Inc.
Via
Business Wire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
October 19, 2022
--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological Endpoints
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Announces Data on SUL-DUR to be Presented at IDWeek 2022
October 12, 2022
Six abstracts selected for presentation, including three oral presentations
From
Entasis Therapeutics Holdings Inc.
Via
GlobeNewswire
A Look Into Healthcare Sector Value Stocks
↗
October 03, 2022
The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...
Via
Benzinga
Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings
↗
September 19, 2022
Via
Benzinga
5 Value Stocks In The Healthcare Sector
↗
September 19, 2022
What are Value Stocks? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
